Regulating prescription drug prices
A paper in JAMA Internal Medicine examines regulatory frameworks of drug pricing in six countries with diverse financing, delivery, and reimbursement systems, ranging from socialized medicine to markets with competing private insurers and providers. The researchers found that these countries have nearly universal health insurance, covering more than 99% of their population, and none have the monopolistic pricing and marketing exclusivity found in the U.S.
FULL STORY AT Leonard Davis Institute →